Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Bonilla, S; Redonnet, A; Noel-Suberville, C; Groubet, R; Pallet, V; Higueret, P
   Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver
   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
   
   S. Bonilla et al., "Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver", J PHYSIOL B, 57(2), 2001, pp. 1-8
2. Bonilla, S; Redonnet, A; Noel-Suberville, C; Groubet, R; Pallet, V; Higueret, P
   Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver
   JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY
   
   S. Bonilla et al., "Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver", J PHYSIOL B, 57(1), 2001, pp. 1-8
3. Kagawa, H; Nomura, S; Nagahama, M; Ozaki, Y; Fukuhara, S
   Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia
   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
   
   H. Kagawa et al., "Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia", CL APPL T-H, 7(2), 2001, pp. 153-157
4. de Barrio, M; Matheu, V; Baeza, ML; Tornero, P; Rubio, M; Zubeldia, JM
   Bezafibrate-induced anaphylactic shock: Unusual clinical presentation
   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY
   
   M. de Barrio et al., "Bezafibrate-induced anaphylactic shock: Unusual clinical presentation", J INVES ALL, 11(1), 2001, pp. 53-55
5. Ohmichi, M; Ikegami, H; Kurachi, H; Node, K; Morishige, K; Nishio, Y; Adachi, K; Matumoto, K; Hayakawa, J; Tasaka, K; Azuma, C; Murata, Y
   Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy
   MATURITAS
   
   M. Ohmichi et al., "Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy", MATURITAS, 38(3), 2001, pp. 279-286
6. Lipscombe, J; Lewis, GF; Cattran, D; Bargman, JM
   Deterioration in renal function associated with fibrate therapy
   CLINICAL NEPHROLOGY
   
   J. Lipscombe et al., "Deterioration in renal function associated with fibrate therapy", CLIN NEPHR, 55(1), 2001, pp. 39-44
7. Vasquez, M; Roglans, N; Cabrero, A; Rodriguez, C; Adzet, T; Alegret, M; Sanchez, RM; Laguna, JC
   Benzafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue
   MOLECULAR AND CELLULAR BIOCHEMISTRY
   
   M. Vasquez et al., "Benzafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue", MOL C BIOCH, 216(1-2), 2001, pp. 71-78
8. Mattu, M; Vannini, A; Coletta, M; Fasano, M; Ascenzi, P
   Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study
   JOURNAL OF INORGANIC BIOCHEMISTRY
   
   M. Mattu et al., "Effect of bezafibrate and clofibrate on the heme-iron geometry of ferrous nitrosylated heme-human serum albumin: an EPR study", J INORG BIO, 84(3-4), 2001, pp. 293-296
9. Meco, JF; Vila, R; Pujol, R; Bros, R; Domenech, P; Fiol, C; Pinto, X
   Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate
   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
   
   J.F. Meco et al., "Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate", J CARDIO PH, 38(2), 2001, pp. 250-258
10. Suzuki, Y; Urano, T; Ihara, H; Nakajima, T; Nagai, N; Takada, Y; Taminato, T; Takada, A
    Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in HepG2 cells
    LIFE SCIENCES
    
    Y. Suzuki et al., "Bezafibrate attenuates the overexpression of plasminogen activator inhibitor-1 messenger RNA by a combination of mono-unsaturated fatty acid and insulin in HepG2 cells", LIFE SCI, 68(16), 2001, pp. 1827-1837
11. Dierkes, J; Westphal, S; Kunstmann, S; Banditt, P; Lossner, A; Luley, C
    Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate
    ATHEROSCLEROSIS
    
    J. Dierkes et al., "Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate", ATHEROSCLER, 158(1), 2001, pp. 161-164
12. Karpe, F; Taskinen, MR; Nieminen, MS; Frick, MH; Kesaniemi, YA; Pasternack, A; Hamsten, A; Syvanne, M
    Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment
    ATHEROSCLEROSIS
    
    F. Karpe et al., "Remnant-like lipoprotein particle cholesterol concentration and progression of coronary and vein-graft atherosclerosis in response to gemfibrozil treatment", ATHEROSCLER, 157(1), 2001, pp. 181-187
13. Yoshikawa, H; Tajiri, Y; Sako, Y; Hashimoto, T; Umeda, F; Nawata, H
    Effects of bezafibrate on beta-cell function of rat pancreatic islets
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    H. Yoshikawa et al., "Effects of bezafibrate on beta-cell function of rat pancreatic islets", EUR J PHARM, 426(3), 2001, pp. 201-206
14. Rodriguez, C; Cabrero, A; Roglans, N; Adzet, T; Sanchez, RM; Vazquez, M; Ciudad, CJ; Laguna, JC
    Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells
    BIOCHEMICAL PHARMACOLOGY
    
    C. Rodriguez et al., "Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells", BIOCH PHARM, 61(3), 2001, pp. 357-364
15. Brown, WV
    Novel approaches to lipid lowering: What is on the horizon?
    AMERICAN JOURNAL OF CARDIOLOGY
    
    W.V. Brown, "Novel approaches to lipid lowering: What is on the horizon?", AM J CARD, 87(5A), 2001, pp. 23B-27B
16. Rustemeijer, C; Schouten, JA; Voerman, HJ; Hensgens, HESJ; Donker, AJM; Heine, RJ
    Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus
    DIABETES-METABOLISM RESEARCH AND REVIEWS
    
    C. Rustemeijer et al., "Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus", DIABET M R, 16(2), 2000, pp. 82-87
17. Dergunov, AD; Smirnova, EA; Merched, A; Visvikis, S; Siest, G; Yakushkin, VV; Tsibulsky, V
    Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    
    A.D. Dergunov et al., "Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E", BBA-MOL C B, 1484(1), 2000, pp. 29-40
18. Paragh, G; Balogh, Z; Seres, I; Harangi, M; Boda, J; Kovacs, P
    Effect of gemfibrozil on HDL-Associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia
    CLINICAL DRUG INVESTIGATION
    
    G. Paragh et al., "Effect of gemfibrozil on HDL-Associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia", CLIN DRUG I, 19(4), 2000, pp. 277-282
19. de Man, FHAF; Jonkers, IJAM; Schwedhelm, E; Smelt, AHM; Onkenhout, W; van Duyvenvoorde, W; Buytenhek, R; Leuven, JAG; Troost, R; van der Laarse, A; Princen, HMG
    Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia - Effects of bezafibrate therapy
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
    
    F.H.A.F. de Man et al., "Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia - Effects of bezafibrate therapy", ART THROM V, 20(11), 2000, pp. 2434-2440
20. Faergeman, O
    Hypertriglyceridemia and the fibrate trials
    CURRENT OPINION IN LIPIDOLOGY
    
    O. Faergeman, "Hypertriglyceridemia and the fibrate trials", CURR OP LIP, 11(6), 2000, pp. 609-614
21. Hernandez-Mijares, A; Lluch, I; Vizcarra, E; Martinez-Triguero, ML; Ascaso, JF; Carmena, R
    Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
    
    A. Hernandez-Mijares et al., "Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects", NUTR MET CA, 10(1), 2000, pp. 1-6
22. Kozak, W; Kluger, MJ; Kozak, A; Wachulec, M; Dokladny, K
    Role of cytochrome P-450 in endogenous antipyresis
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
    
    W. Kozak et al., "Role of cytochrome P-450 in endogenous antipyresis", AM J P-REG, 279(2), 2000, pp. R455-R460
23. Gorski, J; Zendzian-Piotrowska, M; Wolfrum, C; Nawrocki, A; Spener, F
    Effect of sex and bezafibrate on incorporation of blood borne palmitate into lipids of rat liver nuclei
    MOLECULAR AND CELLULAR BIOCHEMISTRY
    
    J. Gorski et al., "Effect of sex and bezafibrate on incorporation of blood borne palmitate into lipids of rat liver nuclei", MOL C BIOCH, 214(1), 2000, pp. 57-62
24. Honeck, H; Gross, V; Erdmann, B; Kargel, E; Neunaber, R; Milia, AF; Schneider, W; Luft, FC; Schunck, WH
    Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice
    HYPERTENSION
    
    H. Honeck et al., "Cytochrome P450-dependent renal arachidonic acid metabolism in desoxycorticosterone acetate-salt hypertensive mice", HYPERTENSIO, 36(4), 2000, pp. 610-616
25. Miyaguchi, S; Ebinuma, H; Imaeda, H; Nitta, Y; Watanabe, T; Saito, H; Ishii, H
    A novel treatment for refractory primary biliary cirrhosis?
    HEPATO-GASTROENTEROLOGY
    
    S. Miyaguchi et al., "A novel treatment for refractory primary biliary cirrhosis?", HEP-GASTRO, 47(36), 2000, pp. 1518-1521
26. Spieker, LE; Noll, G; Hannak, M; Luscher, TF
    Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    
    L.E. Spieker et al., "Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels", J CARDIO PH, 35(3), 2000, pp. 361-365
27. Brites, FD; Fernandez, KM; Yael, MJ; Wikinski, RLW
    Evolution of a patient with a partial deficiency of lecithin : cholesterolacyltransferase
    MEDICINA-BUENOS AIRES
    
    F.D. Brites et al., "Evolution of a patient with a partial deficiency of lecithin : cholesterolacyltransferase", MEDICINA, 60(3), 2000, pp. 406-407
28. Karbowska, J; Kochan, Z; Swierczynski, J
    Differential effect of clofibrate on acetyl-CoA carboxylase mRNA level in rat white and brown adipose tissue
    LIFE SCIENCES
    
    J. Karbowska et al., "Differential effect of clofibrate on acetyl-CoA carboxylase mRNA level in rat white and brown adipose tissue", LIFE SCI, 66(6), 2000, pp. 545-552
29. Lomnicky, Y; Haimov, T; Luria, MH; Friedman, M; Hoffman, A
    Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration
    JOURNAL OF PHARMACEUTICAL SCIENCES
    
    Y. Lomnicky et al., "Pharmacodynamic effects of bezafibrate and niacin combination: Implications of the mode of administration", J PHARM SCI, 89(8), 2000, pp. 1046-1053
30. Lawrence, JW; Kroll, DJ; Eacho, PI
    Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus
    JOURNAL OF LIPID RESEARCH
    
    J.W. Lawrence et al., "Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus", J LIPID RES, 41(9), 2000, pp. 1390-1401
31. Marrapodi, M; Chiang, JYL
    Peroxisome proliferator-activated receptor alpha (PPAR alpha) and agonist inhibit cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription
    JOURNAL OF LIPID RESEARCH
    
    M. Marrapodi e J.Y.L. Chiang, "Peroxisome proliferator-activated receptor alpha (PPAR alpha) and agonist inhibit cholesterol 7 alpha-hydroxylase gene (CYP7A1) transcription", J LIPID RES, 41(4), 2000, pp. 514-520
32. Autran, D; Attia, N; Dedecjus, M; Durlach, V; Girard-Globa, A
    Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment
    ATHEROSCLEROSIS
    
    D. Autran et al., "Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment", ATHEROSCLER, 153(2), 2000, pp. 453-460
33. Stalenhoef, AFH; de Graaf, J; Wittekoek, ME; Bredie, SJH; Demacker, PNM; Kastelein, JJP
    The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia
    ATHEROSCLEROSIS
    
    A.F.H. Stalenhoef et al., "The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertrygliceridemia", ATHEROSCLER, 153(1), 2000, pp. 129-138
34. Totsuka, M; Miyashita, Y; Ito, Y; Watanabe, H; Murano, T; Shirai, K
    Enhancement of preheparin serum lipoprotein lipase mass by bezafbirate administration
    ATHEROSCLEROSIS
    
    M. Totsuka et al., "Enhancement of preheparin serum lipoprotein lipase mass by bezafbirate administration", ATHEROSCLER, 153(1), 2000, pp. 175-179
35. de Man, FH; Nieuwland, R; van der Laarse, A; Romijn, F; Smelt, AHM; Leuven, JAG; Sturk, A
    Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy
    ATHEROSCLEROSIS
    
    F.H. de Man et al., "Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy", ATHEROSCLER, 152(2), 2000, pp. 407-414
36. Pauciullo, P; Borgnino, C; Paoletti, R; Mariani, M; Mancini, M
    Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
    ATHEROSCLEROSIS
    
    P. Pauciullo et al., "Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)", ATHEROSCLER, 150(2), 2000, pp. 429-436
37. Marcello, S; Gladstein, J; Tesone, P; Mas, R
    Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    
    S. Marcello et al., "Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study", CURR THER R, 61(6), 2000, pp. 346-357
38. Hirano, T; Kazumi, T; Yoshino, G
    Long-term efficacy of bezafibrate in reduction of small, dense low-densitylipoprotein by hypotriglyceridemic action
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    
    T. Hirano et al., "Long-term efficacy of bezafibrate in reduction of small, dense low-densitylipoprotein by hypotriglyceridemic action", CURR THER R, 61(3), 2000, pp. 127-136
39. Kurihara, T; Furukawa, M; Tsuchiya, M; Akimoto, M; Ishiguro, H; Hashimoto, H; Niimi, A; Maeda, A; Shigemoto, M; Yamasha, K
    Effect of bezafibrate in the treatment of primary biliary cirrhosis
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    
    T. Kurihara et al., "Effect of bezafibrate in the treatment of primary biliary cirrhosis", CURR THER R, 61(2), 2000, pp. 74-82
40. Schlesinger, Z; Vered, Z; Friedenson, A; Reisin, L; Jafari, J; Flieb, T; Sclarovsky, S; Friedman, Y; Ostfeld, B; Solodky, A; Abinader, E; Rochfleish, S; Palant, A; Schneider, H; Rosenfeld, T; Khalid, S; Wolfson, E; Kishon, Y; Narinsky, R; Rotzak, R; Davidov, A; Levine, G; Zahavi, I; Vitrai, J; Diker, D; Pelled, B; Pardu, J; Galamidi, J; Majadla, R; Laniado, S; Sherf, L; Braun, S; Eschar, Y; Caspi, A; Arditi, A; Botwin, S; Arkavi, L; Ziv, M; David, D; Weisenberg, D; Kohanovski, M; Meisel, S; Rougin, N; Yahalom, M; Glusman-Vazan, A; Markiewitz, W; Motlak, D; Lessick, J; Kagan, G; Marmour, A; Flich, M; Solomon, R; Tzivoni, D; Zion, M; Balkin, J; Rabinowitz, B; Barasch, E; Brill, Z; Aharon, L; Asman, A; Battler, A; Gueron, M; Cristal, N; Liel, N; Tsatskis, B; Henkin, J
    Secondary prevention by raising HDL cholesterol and reducing triglyceridesin patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
    CIRCULATION
    
    Z. Schlesinger et al., "Secondary prevention by raising HDL cholesterol and reducing triglyceridesin patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study", CIRCULATION, 102(1), 2000, pp. 21-27
41. Cabrero, A; Alegret, M; Sanchez, R; Adzet, T; Laguna, JC; Vazquez, M
    Peroxisome proliferator-activated receptor alpha (PPAR alpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    
    A. Cabrero et al., "Peroxisome proliferator-activated receptor alpha (PPAR alpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes", ARCH BIOCH, 380(2), 2000, pp. 353-359
42. Feher, MD; Caslake, M; Foxton, J; Cox, A; Packard, CJ
    Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate
    DIABETES-METABOLISM RESEARCH AND REVIEWS
    
    M.D. Feher et al., "Atherogenic lipoprotein phenotype in type 2 diabetes: Reversal with micronised fenofibrate", DIABET M R, 15(6), 1999, pp. 395-399
43. Wolfrum, C; Buhlmann, C; Rolf, B; Borchers, T; Spener, F
    Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    
    C. Wolfrum et al., "Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake", BBA-MOL C B, 1437(2), 1999, pp. 194-201
44. Iwasaki, S; Tsuda, K; Ueta, H; Aono, R; Ono, M; Saibara, T; Maeda, T; Onishi, S
    Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis
    HEPATOLOGY RESEARCH
    
    S. Iwasaki et al., "Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis", HEPATOL RES, 16(1), 1999, pp. 12-18
45. Scatena, R; Nocca, G; De Sole, P; Rumi, C; Puggioni, P; Remiddi, F; Bottoni, P; Ficarra, S; Giardina, B
    Bezafibrate as differentiating factor of human myeloid leukemia cells
    CELL DEATH AND DIFFERENTIATION
    
    R. Scatena et al., "Bezafibrate as differentiating factor of human myeloid leukemia cells", CELL DEAT D, 6(8), 1999, pp. 781-787
46. Krobot, KJ; Wenke, K; Reichart, B
    Simvastatin after orthotopic heart transplantation - Costs and consequences
    PHARMACOECONOMICS
    
    K.J. Krobot et al., "Simvastatin after orthotopic heart transplantation - Costs and consequences", PHARMACOECO, 15(3), 1999, pp. 279-289
47. Hoffman, A; Lomnicky, Y; Luria, MH; Gilhar, D; Friedman, M
    Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained releasepreparation of the drug
    PHARMACEUTICAL RESEARCH
    
    A. Hoffman et al., "Improved lipid lowering activity of bezafibrate following continuous gastrointestinal administration: Pharmacodynamic rationale for sustained releasepreparation of the drug", PHARM RES, 16(7), 1999, pp. 1093-1097
48. Meyer, K; Volkl, A; Endele, R; Kuhnle, HF; Pill, J
    Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPAR alpha)
    ARCHIVES OF TOXICOLOGY
    
    K. Meyer et al., "Species differences in induction of hepatic enzymes by BM 17.0744, an activator of peroxisome proliferator-activated receptor alpha (PPAR alpha)", ARCH TOXIC, 73(8-9), 1999, pp. 440-450
49. Beggs, PW; Clark, DWJ; Williams, SM; Coulter, DM
    A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP)
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    P.W. Beggs et al., "A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP)", BR J CL PH, 47(1), 1999, pp. 99-104
50. Mooney, A
    Treating patients with hypertriglyceridaemia saves lives: Triglyceride revisited
    CURRENT MEDICAL RESEARCH AND OPINION
    
    A. Mooney, "Treating patients with hypertriglyceridaemia saves lives: Triglyceride revisited", CURR MED R, 15(2), 1999, pp. 65-77
51. Kawamura, I; Yamamoto, N; Sakai, F; Yamazaki, H; Goto, T
    Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice
    ANTICANCER RESEARCH
    
    I. Kawamura et al., "Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice", ANTICANC R, 19(5B), 1999, pp. 4099-4103
52. Hottelart, C; El Esper, N; Achard, JM; Pruna, A; Fournier, A
    Fenofibrate increases creatininemia but does not alter glomerular filtration rate in patients with mild renal insufficiency
    NEPHROLOGIE
    
    C. Hottelart et al., "Fenofibrate increases creatininemia but does not alter glomerular filtration rate in patients with mild renal insufficiency", NEPHROLOGIE, 20(1), 1999, pp. 41-44
53. Papadakis, JA; Ganotakis, ES; Jagroop, IA; Winder, AF; Mikhailidis, DP
    Statin plus fibrate combination therapy - Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
    INTERNATIONAL JOURNAL OF CARDIOLOGY
    
    J.A. Papadakis et al., "Statin plus fibrate combination therapy - Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease", INT J CARD, 69(3), 1999, pp. 237-244
54. Hunninghake, DB
    Pharmacologic management of triglycerides
    CLINICAL CARDIOLOGY
    
    D.B. Hunninghake, "Pharmacologic management of triglycerides", CLIN CARD, 22(6), 1999, pp. II44-II48
55. Ou, JF; Saku, K; Jimi, S; Liao, YL; Ohta, T; Zhang, B; Arakawa, K
    Combined effects of probucol and bezafibrate on lipoprotein metabolism andliver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION
    
    J.F. Ou et al., "Combined effects of probucol and bezafibrate on lipoprotein metabolism andliver cholesteryl ester transfer protein mRNA in cholesterol-fed rabbits", JPN CIRC J, 63(6), 1999, pp. 471-477
56. Brown, PJ; Winegar, DA; Plunket, KD; Moore, LB; Lewis, MC; Wilson, JG; Sundseth, SS; Koble, CS; Wu, ZD; Chapman, JM; Lehmann, JM; Kliewer, SA; Willson, TM
    A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity
    JOURNAL OF MEDICINAL CHEMISTRY
    
    P.J. Brown et al., "A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPAR alpha agonist with potent lipid-lowering activity", J MED CHEM, 42(19), 1999, pp. 3785-3788
57. Otto, C; Schwandt, P
    When statins are not enough to lower lipid levels - Benefits and risks of lipid-lowering combination therapy, especially the combination statin and fibrate
    INTERNIST
    
    C. Otto e P. Schwandt, "When statins are not enough to lower lipid levels - Benefits and risks of lipid-lowering combination therapy, especially the combination statin and fibrate", INTERNIST, 40(12), 1999, pp. 1338-1345
58. Karbowska, J; Kochan, Z; Zelewski, L; Swierczynski, J
    Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression
    EUROPEAN JOURNAL OF PHARMACOLOGY
    
    J. Karbowska et al., "Tissue-specific effect of clofibrate on rat lipogenic enzyme gene expression", EUR J PHARM, 370(3), 1999, pp. 329-336
59. VANCE DE; WALKEY CJ
    ROLES FOR THE METHYLATION OF PHOSPHATIDYLETHANOLAMINE
    Current opinion in lipidology
    
    D.E. Vance e C.J. Walkey, "ROLES FOR THE METHYLATION OF PHOSPHATIDYLETHANOLAMINE", Current opinion in lipidology, 9(2), 1998, pp. 125-130
60. SIAMOPOULOS KC; ELISAF M; KATOPODIS K
    IATROGENIC HYPERKALEMIA - POINTS TO CONSIDER IN DIAGNOSIS AND MANAGEMENT
    Nephrology, dialysis, transplantation
    
    K.C. Siamopoulos et al., "IATROGENIC HYPERKALEMIA - POINTS TO CONSIDER IN DIAGNOSIS AND MANAGEMENT", Nephrology, dialysis, transplantation, 13(9), 1998, pp. 2402-2406
61. AGRAWAL B; KOPECKY J; KRANZLIN B; ROHMEISS P; PILL J; GRETZ N
    ACUTE EFFECTS OF BEZAFIBRATE ON BLOOD-PRESSURE AND RENAL HEMODYNAMICSIN SHR AND WKY RATS
    Nephrology, dialysis, transplantation
    
    B. Agrawal et al., "ACUTE EFFECTS OF BEZAFIBRATE ON BLOOD-PRESSURE AND RENAL HEMODYNAMICSIN SHR AND WKY RATS", Nephrology, dialysis, transplantation, 13(2), 1998, pp. 333-339
62. HAYASHI K; KURUSHIMA H; KUGA Y; SHINGU T; TANAKA K; YASUNOBU Y; NOMURA K; OHTANI H; HIRAGA T; TOYOTA Y; KATANO T; SAKAIOHTA K; KAJIYAMA G
    COMPARISON OF THE EFFECT OF BEZAFIBRATE ON IMPROVEMENT OF ATHEROGENICLIPOPROTEINS IN JAPANESE FAMILIAL COMBINED HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT IMPAIRED GLUCOSE-TOLERANCE
    Cardiovascular drugs and therapy
    
    K. Hayashi et al., "COMPARISON OF THE EFFECT OF BEZAFIBRATE ON IMPROVEMENT OF ATHEROGENICLIPOPROTEINS IN JAPANESE FAMILIAL COMBINED HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT IMPAIRED GLUCOSE-TOLERANCE", Cardiovascular drugs and therapy, 12(1), 1998, pp. 3-12
63. GOTO H; YAMASHITA S; MAKITA T
    PREVENTION OF OROTIC-ACID-INDUCED FATTY LIVER IN MALE RATS BY DEHYDROEPIANDROSTERONE AND OR PHENOBARBITAL/
    Journal of veterinary medical science
    
    H. Goto et al., "PREVENTION OF OROTIC-ACID-INDUCED FATTY LIVER IN MALE RATS BY DEHYDROEPIANDROSTERONE AND OR PHENOBARBITAL/", Journal of veterinary medical science, 60(4), 1998, pp. 513-517
64. NEUMAN MP; NEUMAN FJ; NEUMAN J; ROCCELLA MC; MONTENERO Y; BRUETMAN JE; GONZALEZ C
    EFFECT OF BEZAFIBRATE ON LIPID-PEROXIDATION IN PATIENTS WITH HYPERTRIGLYCERIDEMIA
    Advances in therapy
    
    M.P. Neuman et al., "EFFECT OF BEZAFIBRATE ON LIPID-PEROXIDATION IN PATIENTS WITH HYPERTRIGLYCERIDEMIA", Advances in therapy, 15(3), 1998, pp. 142-150
65. Mikhailidis, DP; Ganotakis, ES; Spyropoulos, KA; Jagroop, IA; Byrne, DJ; Winder, AF
    Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice
    INTERNATIONAL ANGIOLOGY
    
    D.P. Mikhailidis et al., "Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice", INT ANGIOL, 17(4), 1998, pp. 225-233
66. MURAKAMI T; NAGAMURA Y; HIRANO K
    ETHANOLAMINE STIMULATES REPAIR PROCESSES IN ACUTE CCL4 DAMAGE OF MOUSE-LIVER
    Toxicology letters
    
    T. Murakami et al., "ETHANOLAMINE STIMULATES REPAIR PROCESSES IN ACUTE CCL4 DAMAGE OF MOUSE-LIVER", Toxicology letters, 94(2), 1998, pp. 137-144
67. MONTALESCOT G; COLLET JP; CHOUSSAT R; THOMAS D
    FIBRINOGEN AS A RISK FACTOR FOR CORONARY HEART-DISEASE
    European heart journal
    
    G. Montalescot et al., "FIBRINOGEN AS A RISK FACTOR FOR CORONARY HEART-DISEASE", European heart journal, 19, 1998, pp. 11-17
68. ERICSSON CG
    RESULTS OF THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND AN UPDATE ON TRIALS NOW IN PROGRESS
    European heart journal
    
    C.G. Ericsson, "RESULTS OF THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND AN UPDATE ON TRIALS NOW IN PROGRESS", European heart journal, 19, 1998, pp. 37-41
69. GOLDBOURT U; BRUNNER D; BEHAR S; REICHERREISS H
    BASE-LINE CHARACTERISTICS OF PATIENTS PARTICIPATING IN THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY - THE BIP (BEZAFIBRATE INFARCTION PREVENTION) STUDY-GROUP
    European heart journal
    
    U. Goldbourt et al., "BASE-LINE CHARACTERISTICS OF PATIENTS PARTICIPATING IN THE BEZAFIBRATE INFARCTION PREVENTION (BIP) STUDY - THE BIP (BEZAFIBRATE INFARCTION PREVENTION) STUDY-GROUP", European heart journal, 19, 1998, pp. 42-47
70. Susekov, AV; Tvorogova, MG; Arabidze, GG; Kukharchuk, VV
    Lipanor treatment of atherogenic hyperlipoproteinemia
    TERAPEVTICHESKII ARKHIV
    
    A.V. Susekov et al., "Lipanor treatment of atherogenic hyperlipoproteinemia", TERAPEVT AR, 70(9), 1998, pp. 57-61
71. Vazquez-Chavez, C; Salinas-Orozco, S; Gomez-Diaz, RA; Rosso-Juarez, MM; Moreno-Vazquez, K; Nissen-Torres, T; Arguero-Sanchez, R
    Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia
    REVISTA DE INVESTIGACION CLINICA
    
    C. Vazquez-Chavez et al., "Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia", REV INV CLI, 50(6), 1998, pp. 491-496
72. JOVINGE S; HAMSTEN A; TORNVALL P; PROUDLER A; BAVENHOLM P; ERICSSON CG; GODSLAND I; DEFAIRE U; NILSSON J
    EVIDENCE FOR A ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA IN DISTURBANCES OFTRIGLYCERIDE AND GLUCOSE-METABOLISM PREDISPOSING TO CORONARY HEART-DISEASE
    Metabolism, clinical and experimental
    
    S. Jovinge et al., "EVIDENCE FOR A ROLE OF TUMOR-NECROSIS-FACTOR-ALPHA IN DISTURBANCES OFTRIGLYCERIDE AND GLUCOSE-METABOLISM PREDISPOSING TO CORONARY HEART-DISEASE", Metabolism, clinical and experimental, 47(1), 1998, pp. 113-118
73. INOUE I; NOJI S; AWATA T; TAKAHASHI K; NAKAJIMA T; SONODA M; KOMODA T; KATAYAMA S
    BEZAFIBRATE HAS AN ANTIOXIDANT EFFECT - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA IS ASSOCIATED WITH CU2-DISMUTASE IN THE LIVER(, ZN2+ SUPEROXIDE)
    Life sciences
    
    I. Inoue et al., "BEZAFIBRATE HAS AN ANTIOXIDANT EFFECT - PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA IS ASSOCIATED WITH CU2-DISMUTASE IN THE LIVER(, ZN2+ SUPEROXIDE)", Life sciences, 63(2), 1998, pp. 135-144
74. SUZUKI R; SURUGA K; GODA T; TAKASE S
    PEROXISOME PROLIFERATOR ENHANCES GENE-EXPRESSION OF CELLULAR RETINOL-BINDING PROTEIN, TYPE-II IN CACO-2 CELLS
    Life sciences
    
    R. Suzuki et al., "PEROXISOME PROLIFERATOR ENHANCES GENE-EXPRESSION OF CELLULAR RETINOL-BINDING PROTEIN, TYPE-II IN CACO-2 CELLS", Life sciences, 62(10), 1998, pp. 861-871
75. Lomnicky, Y; Friedman, M; Luria, MH; Raz, I; Hoffman, A
    The effect of the mode of administration on the hypolipidaemic activity ofniacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats
    JOURNAL OF PHARMACY AND PHARMACOLOGY
    
    Y. Lomnicky et al., "The effect of the mode of administration on the hypolipidaemic activity ofniacin: Continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats", J PHARM PHA, 50(11), 1998, pp. 1233-1239
76. DURRINGTON PN; MACKNESS MI; BHATNAGAR D; JULIER K; PRAIS H; ARROL S; MORGAN J; WOOD GNI
    EFFECTS OF 2 DIFFERENT FIBRIC ACID-DERIVATIVES ON LIPOPROTEINS, CHOLESTERYL ESTER TRANSFER, FIBRINOGEN, PLASMINOGEN-ACTIVATOR INHIBITOR ANDPARAOXONASE ACTIVITY IN TYPE IIB HYPERLIPOPROTEINEMIA
    Atherosclerosis
    
    P.N. Durrington et al., "EFFECTS OF 2 DIFFERENT FIBRIC ACID-DERIVATIVES ON LIPOPROTEINS, CHOLESTERYL ESTER TRANSFER, FIBRINOGEN, PLASMINOGEN-ACTIVATOR INHIBITOR ANDPARAOXONASE ACTIVITY IN TYPE IIB HYPERLIPOPROTEINEMIA", Atherosclerosis, 138(1), 1998, pp. 217-225
77. NARUSZEWICZ M
    FROM THE HISTORY OF INVESTIGATIONS ON THE OXIDATIVE MODIFICATION OF SMALL DENSE LDL
    Atherosclerosis
    
    M. Naruszewicz, "FROM THE HISTORY OF INVESTIGATIONS ON THE OXIDATIVE MODIFICATION OF SMALL DENSE LDL", Atherosclerosis, 137(2), 1998, pp. 439-439
78. GAW A
    EVIDENCE BASED APPROACH FOR THE MANAGEMENT OF MIXED HYPERLIPIDEMIA
    Atherosclerosis (Amsterdam)
    
    A. Gaw, "EVIDENCE BASED APPROACH FOR THE MANAGEMENT OF MIXED HYPERLIPIDEMIA", Atherosclerosis (Amsterdam), 137, 1998, pp. 97-100
79. Uchida, K; Reilly, MP; Abraham, DJ; Asakura, T
    Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits
    JAPANESE JOURNAL OF PHYSIOLOGY
    
    K. Uchida et al., "Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits", JPN J PHYSL, 48(6), 1998, pp. 439-444
80. Anchisi, C; Fadda, AM; Maccioni, AM; Dessi, S
    Determination of bezafibrate concentration by high performance liquid-chromatography in serum of rats treated with lead nitrate
    FARMACO
    
    C. Anchisi et al., "Determination of bezafibrate concentration by high performance liquid-chromatography in serum of rats treated with lead nitrate", FARMACO, 53(10-11), 1998, pp. 690-692
81. ALEGRET M; VERD JC; DIAZ C; HERNANDEZ G; ADZET T; SANCHEZ RM; LAGUNA JC
    EFFECT OF HYPOLIPIDEMIC DRUGS ON KEY ENZYME-ACTIVITIES RELATED TO LIPID-METABOLISM IN NORMOLIPIDEMIC RABBITS
    European journal of pharmacology
    
    M. Alegret et al., "EFFECT OF HYPOLIPIDEMIC DRUGS ON KEY ENZYME-ACTIVITIES RELATED TO LIPID-METABOLISM IN NORMOLIPIDEMIC RABBITS", European journal of pharmacology, 347(2-3), 1998, pp. 283-291
82. BINSACK R; STEGMEIER K; DORGE L; VOLKL A
    BEZAFIBRATE DOWN-REGULATES FIBRINOGEN BIOSYNTHESIS IN HUMAN HEPATOMA HEPG2 CELLS
    European journal of clinical investigation
    
    R. Binsack et al., "BEZAFIBRATE DOWN-REGULATES FIBRINOGEN BIOSYNTHESIS IN HUMAN HEPATOMA HEPG2 CELLS", European journal of clinical investigation, 28(2), 1998, pp. 151-163
83. NAKAMURA Y; OHYA Y; ONAKA U; FUJII K; ABE I; FUJISHIMA M
    INHIBITORY-ACTION OF INSULIN-SENSITIZING AGENTS ON CALCIUM CHANNELS IN SMOOTH-MUSCLE CELLS FROM RESISTANCE ARTERIES OF GUINEA-PIG
    British Journal of Pharmacology
    
    Y. Nakamura et al., "INHIBITORY-ACTION OF INSULIN-SENSITIZING AGENTS ON CALCIUM CHANNELS IN SMOOTH-MUSCLE CELLS FROM RESISTANCE ARTERIES OF GUINEA-PIG", British Journal of Pharmacology, 123(4), 1998, pp. 675-682
84. FOUCAUD L; NIOT I; KANDA T; BESNARD P
    INDIRECT DEXAMETHASONE DOWN-REGULATION OF THE LIVER FATTY-ACID-BINDING PROTEIN EXPRESSION IN RAT-LIVER
    Biochimica et biophysica acta, L. Lipids and lipid metabolism
    
    L. Foucaud et al., "INDIRECT DEXAMETHASONE DOWN-REGULATION OF THE LIVER FATTY-ACID-BINDING PROTEIN EXPRESSION IN RAT-LIVER", Biochimica et biophysica acta, L. Lipids and lipid metabolism, 1391(2), 1998, pp. 204-212
85. WIERZBICKI AS; LUMB PJ; CHEUNG J; CROOK MA
    FENOFIBRATE PLUS SIMVASTATIN THERAPY VERSUS SIMVASTATIN PLUS CHOLESTYRAMINE THERAPY FOR FAMILIAL HYPERCHOLESTEROLEMIA
    Quarterly Journal of Medicine
    
    A.S. Wierzbicki et al., "FENOFIBRATE PLUS SIMVASTATIN THERAPY VERSUS SIMVASTATIN PLUS CHOLESTYRAMINE THERAPY FOR FAMILIAL HYPERCHOLESTEROLEMIA", Quarterly Journal of Medicine, 90(10), 1997, pp. 631-634
86. GOTO D; OKIMOTO T; ONO M; SHIMOTSU H; ABE K; TSUJITA Y; KUWANO M
    UP-REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR BY GEMFIBROZIL, A HYPOLIPIDEMIC AGENT, IN HUMAN HEPATOMA-CELLS THROUGH STABILIZATION OF MESSENGER-RNA TRANSCRIPTS
    Arteriosclerosis, thrombosis, and vascular biology
    
    D. Goto et al., "UP-REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR BY GEMFIBROZIL, A HYPOLIPIDEMIC AGENT, IN HUMAN HEPATOMA-CELLS THROUGH STABILIZATION OF MESSENGER-RNA TRANSCRIPTS", Arteriosclerosis, thrombosis, and vascular biology, 17(11), 1997, pp. 2707-2712
87. BAUMGART E; SCHAD A; VOLKL A; FAHIMI HD
    DETECTION OF MESSENGER-RNAS ENCODING PEROXISOMAL PROTEINS BY NONRADIOACTIVE IN-SITU HYBRIDIZATION WITH DIGOXIGENIN-LABELED CRNAS
    HISTOCHEMISTRY AND CELL BIOLOGY
    
    E. Baumgart et al., "DETECTION OF MESSENGER-RNAS ENCODING PEROXISOMAL PROTEINS BY NONRADIOACTIVE IN-SITU HYBRIDIZATION WITH DIGOXIGENIN-LABELED CRNAS", HISTOCHEM C, 108(4-5), 1997, pp. 371-379
88. LAVILLE AE; SOLA R; MOTTA C; PLANA N; HERAS M; RIBALTA J; MASANA L
    PHYSICOCHEMICAL CHANGES IN HDL3 AFTER BEZAFIBRATE TREATMENT - INFLUENCE ON FREE-CHOLESTEROL EFFLUX FROM HUMAN FIBROBLASTS
    Cardiovascular drugs and therapy
    
    A.E. Laville et al., "PHYSICOCHEMICAL CHANGES IN HDL3 AFTER BEZAFIBRATE TREATMENT - INFLUENCE ON FREE-CHOLESTEROL EFFLUX FROM HUMAN FIBROBLASTS", Cardiovascular drugs and therapy, 11(5), 1997, pp. 653-658
89. DEFAIRE U; ERICSSON CG; GRIP L; NILSSON J; SVANE B; HAMSTEN A
    RETARDATION OF CORONARY ATHEROSCLEROSIS - THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND OTHER ANGIOGRAPHIC TRIALS
    Cardiovascular drugs and therapy
    
    U. Defaire et al., "RETARDATION OF CORONARY ATHEROSCLEROSIS - THE BEZAFIBRATE CORONARY ATHEROSCLEROSIS INTERVENTION TRIAL (BECAIT) AND OTHER ANGIOGRAPHIC TRIALS", Cardiovascular drugs and therapy, 11, 1997, pp. 257-263
90. NAKAI A; NISHIKATA M; UCHIDA T; ICHIKAWA M; MATSUYAMA K
    ENHANCED MYOPATHY FOLLOWING ADMINISTRATION OF HYPOLIPIDEMIC AGENTS UNDER URETHANE ANESTHESIA
    Biological & pharmaceutical bulletin
    
    A. Nakai et al., "ENHANCED MYOPATHY FOLLOWING ADMINISTRATION OF HYPOLIPIDEMIC AGENTS UNDER URETHANE ANESTHESIA", Biological & pharmaceutical bulletin, 20(1), 1997, pp. 104-106
91. KONDO K; MAKITA T
    MORPHOMETRY OF ABNORMAL PEROXISOMES INDUCED BY WITHDRAWAL OF BEZAFIBRATE, A HYPOLIPIDEMIC DRUG IN MALE-RAT HEPATOCYTES
    Journal of veterinary medical science
    
    K. Kondo e T. Makita, "MORPHOMETRY OF ABNORMAL PEROXISOMES INDUCED BY WITHDRAWAL OF BEZAFIBRATE, A HYPOLIPIDEMIC DRUG IN MALE-RAT HEPATOCYTES", Journal of veterinary medical science, 59(4), 1997, pp. 297-299
92. GOLDBERG AC
    THE IMPACT OF LIPID-LOWERING IN CORONARY-ARTERY DISEASE
    Current opinion in cardiology
    
    A.C. Goldberg, "THE IMPACT OF LIPID-LOWERING IN CORONARY-ARTERY DISEASE", Current opinion in cardiology, 12(5), 1997, pp. 488-493
93. POIRIER H; NIOT I; DEGRACE P; MONNOT MC; BERNARD A; BESNARD P
    FATTY-ACID REGULATION OF FATTY-ACID-BINDING PROTEIN EXPRESSION IN THESMALL-INTESTINE
    American journal of physiology: Gastrointestinal and liver physiology
    
    H. Poirier et al., "FATTY-ACID REGULATION OF FATTY-ACID-BINDING PROTEIN EXPRESSION IN THESMALL-INTESTINE", American journal of physiology: Gastrointestinal and liver physiology, 36(2), 1997, pp. 289-295
94. SUGIYAMA H; YAMADA J; TAKAMA H; KODAMA Y; WATANABE T; TAGUCHI T; SUGA T
    PHOTOAFFINITY-LABELING OF PEROXISOME PROLIFERATOR BINDING-PROTEINS INRAT HEPATOCYTES - DEHYDROEPIANDROSTERONE SULFATE-BINDING AND BEZAFIBRATE-BINDING PROTEINS
    Biochimica et biophysica acta. Protein structure and molecular enzymology
    
    H. Sugiyama et al., "PHOTOAFFINITY-LABELING OF PEROXISOME PROLIFERATOR BINDING-PROTEINS INRAT HEPATOCYTES - DEHYDROEPIANDROSTERONE SULFATE-BINDING AND BEZAFIBRATE-BINDING PROTEINS", Biochimica et biophysica acta. Protein structure and molecular enzymology, 1339(2), 1997, pp. 321-330
95. YOSHINARI M; YAMAMOTO M; WAKISAKA M; IWASE M; TAKANO K; FUJISHIMA M
    EFFECT OF BEZAFIBRATE ON HYPERCOAGULABILITY ASSESSED BY FLUOROGENIC PROTHROMBIN TIME IN HYPERLIPIDEMIC PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS
    Thrombosis research
    
    M. Yoshinari et al., "EFFECT OF BEZAFIBRATE ON HYPERCOAGULABILITY ASSESSED BY FLUOROGENIC PROTHROMBIN TIME IN HYPERLIPIDEMIC PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS", Thrombosis research, 86(6), 1997, pp. 443-451
96. BERINGER TRO
    WARFARIN POTENTIATION WITH BEZAFIBRATE
    Postgraduate medical journal
    
    T.R.O. Beringer, "WARFARIN POTENTIATION WITH BEZAFIBRATE", Postgraduate medical journal, 73(864), 1997, pp. 657-658
97. INOUE I; NOJI S; SHEN MZ; TAKAHASHI K; KATAYAMA S
    THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA (PPAR-ALPHA) REGULATES THE PLASMA THIOBARBITURIC ACID-REACTIVE SUBSTANCE (TBARS) LEVEL
    Biochemical and biophysical research communications
    
    I. Inoue et al., "THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA (PPAR-ALPHA) REGULATES THE PLASMA THIOBARBITURIC ACID-REACTIVE SUBSTANCE (TBARS) LEVEL", Biochemical and biophysical research communications, 237(3), 1997, pp. 606-610
98. KONDO K; MAKITA T
    INHIBITION OF PEROXISOMAL DEGRADATION BY 3-METHYLADENINE (3MA) IN PRIMARY CULTURES OF RAT HEPATOCYTES
    The Anatomical record
    
    K. Kondo e T. Makita, "INHIBITION OF PEROXISOMAL DEGRADATION BY 3-METHYLADENINE (3MA) IN PRIMARY CULTURES OF RAT HEPATOCYTES", The Anatomical record, 247(4), 1997, pp. 449-454
99. MASNATTA LD; CUNIBERTI LA; REY RH; WERBA JP
    DETERMINATION OF BEZAFIBRATE, CIPROFIBRATE AND FENOFIBRIC ACID IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    Journal of chromatography B. Biomedical applications
    
    L.D. Masnatta et al., "DETERMINATION OF BEZAFIBRATE, CIPROFIBRATE AND FENOFIBRIC ACID IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY", Journal of chromatography B. Biomedical applications, 687(2), 1996, pp. 437-442
100. YAMAMOTO K; FUKUDA N; ZHANG L; SAKAI T
     ALTERED HEPATIC-METABOLISM OF FATTY-ACIDS IN RATS FED A HYPOLIPEMIC DRUG, FENOFIBRATE
     Pharmacological research
     
     K. Yamamoto et al., "ALTERED HEPATIC-METABOLISM OF FATTY-ACIDS IN RATS FED A HYPOLIPEMIC DRUG, FENOFIBRATE", Pharmacological research, 33(6), 1996, pp. 337-342